REVIEW OF CYTOKINE STORM SYNDROME: IMMUNOLOGICAL MECHANISMS AND CLINICAL IMPLICATIONS

Abstract

Cytokine Storm Syndrome (CSS) represents a critical hyperinflammatory state characterized by uncontrolled immune activation and excessive cytokine release, leading to multi-organ dysfunction and high mortality. This review synthesizes current evidence on the immunopathogenesis, diagnostic frameworks, and evolving therapeutic strategies of CSS. A structured narrative review methodology was employed, integrating recent clinical and experimental literature on conditions associated with CSS, including infections, malignancies, autoimmune disorders, and immunotherapies such as CAR T-cell therapy. The findings highlight that impaired cytotoxic function of CD8⁺ T lymphocytes and natural killer cells, primarily due to defective perforin-mediated pathways, drives persistent immune activation and excessive production of pro-inflammatory cytokines, including interferon-γ, interleukin (IL)-6, IL-1β, and tumor necrosis factor-α. This dysregulated cascade establishes a self-amplifying inflammatory loop, clinically manifesting as persistent fever, cytopenias, hepatosplenomegaly, coagulopathy, and progressive organ failure. Diagnostic approaches remain age-dependent, with the HLH-2004 criteria applied in pediatric populations and the HScore (≥169 demonstrating >90% diagnostic accuracy) utilized in adults. Therapeutic paradigms have transitioned from conventional cytotoxic regimens, such as etoposide-based protocols with moderate long-term survival outcomes, toward targeted immunomodulatory therapies. Agents including tocilizumab (IL-6 inhibition), anakinra (IL-1 blockade), and emapalumab (interferon-γ neutralization) demonstrate improved clinical outcomes. Additionally, evidence from the COVID-19 pandemic underscores the efficacy of corticosteroids, particularly dexamethasone, in reducing mortality by mitigating hyperinflammation. Despite these advances, significant gaps persist, including the absence of standardized diagnostic criteria, limited availability of rapid diagnostic tools, and insufficient large-scale clinical trials. The review emphasizes the critical importance of early recognition and personalized therapeutic approaches in improving patient outcomes. Future research should prioritize the development of universal diagnostic frameworks, exploration of combination and pathway-targeted therapies, such as modulation of autophagy, and the establishment of global patient registries to enhance evidence-based management of CSS.